# US 8,277,809 B2 · CXCL13 antagonists and their use for the treatment of inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,809 B2
- Document ID: US8277809B2
- Status: Granted
- Kind: B2
- Application number: 11/738,019
- Filed: 2007-04-20
- Published: 2008-01-17
- Granted: 2012-10-02
- Earliest claimed: 2006-04-21
- Assignees: Centocor, Inc.
- Inventors: Peter Bugelski; Anuk Das; Donald E. Griswold; Bailin Liang; Li Li; Robert T. Sarisky; Xiaozhou Shang
- Web page: https://patentgrep.com/patent/US8277809B2

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNFα antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.

## Claims

### Claim 1

A method for treating a CXCL13 activity-related disorder in a cell, tissue, organ or animal comprising:
administering to the cell, tissue, organ or animal a CXCL13 binding monoclonal antibody or a CXCL13 binding fragment thereof in an amount effective to inhibit the CXCL13 activity in said cell, tissue, organ or animal; and
administering to the cell, tissue, organ or animal a TNFα binding monoclonal antibody or a TNFα binding fragment thereof in an amount effective to inhibit TNFα activity in said cell, tissue, organ or animal, wherein the CXCL13 activity-related disorder is chronic obstructive pulmonary disorder (COPD) or systemic lupus erythematosus.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody fragment is a Fab, Fab′, or F(ab′)2 fragment.

### Claim 3 (depends on 1)

The method of claim 1, wherein the animal is a mammal.

### Claim 4 (depends on 3)

The method of claim 3, wherein at least one monoclonal antibody or fragment is administered by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

### Claim 5 (depends on 4)

The method of claim 4, wherein a monoclonal antibody or fragment is administered in the amount of from about 0.05 mg/kg to about 30.0 mg/kg body weight of said mammal.

### Claim 6 (depends on 4)

The method of claim 4, wherein the mammal is a human patient.

### Claim 7 (depends on 4)

The method of claim 4, wherein a monoclonal antibody or fragment is administered intraperitoneally.

### Claim 8 (depends on 5)

The method of claim 5, wherein a monoclonal antibody or fragment is administered in a bolus dose followed by an infusion of said antibody.

### Claim 9

A method for treating an animal with systemic lupus erythematosus comprising:
a) providing a of CXCL-13 binding antibody or CXCL-13 binding fragment of an antibody to the animal, and
b) providing a of TNFα binding antibody or a TNFα binding fragment of an antibody to the animal;
wherein each antibody or binding fragment is provided in an amount effective to cause a decrease in a symptom of systemic lupus erythematosus in the animal.

### Claim 10 (depends on 9)

The method of claim 9, wherein the animal is a mammal.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mammal is a human.

### Claim 12 (depends on 9)

The method of claim 9, wherein the amount of each antibody or binding fragment of an antibody provided is from about 0.05 mg per kg to about 50.0 mg per kg body weight of the animal.

### Claim 13 (depends on 12)

The method of claim 12, wherein the amount of each antibody or binding fragment of an antibody provided is from about 25 mg per kg body weight of the animal to about 40 mg per kg body weight of the animal.

### Claim 14 (depends on 9)

The method of claim 9, wherein the symptom of systemic lupus erythematosus is the number of periarterial lymphocyte infiltrate foci identified by examination of the kidney tissues.

### Claim 15 (depends on 9)

The method of claim 9, wherein the symptom of systemic lupus erythematosus is the ratio of total urine protein to total urine creatinine.
